KEVZARA MOA

Kevzara helps inhibit the effects of chronically elevated IL-6.1,2

KEVZARA helps inhibit the effects of chronically elevated IL-6

KEVZARA targets and binds with high affinity to soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), thereby inhibiting IL-6 signaling1,2

  • KEVZARA is a fully human IL-6R inhibitor approved for RA1,2

KEVZARA MOA3,4

KEVZARA® (sarilumab) targets and binds with high affinity to soluble and membrane-bound IL-6 receptors(sIL-IR and mIL-6R), thereby inhibiting IL-6 signaling

The clinical significance of these findings is unknown.

  • *Following single-dose subcutaneous administration of sarilumab in patients with RA, absolute neutrophil counts decreased to the nadir between 3 and 4 days and thereafter recovered towards baseline.1

IL-6=interleukin 6; sIL-6R=soluble interleukin-6 receptor; mIL-6R=membrane-bound interleukin-6 receptor; RA=rheumatoid arthritis; GP130=glycoprotein 130; FLSs=fibroblast-like synoviocytes.

Watch how KEVZARA helps inhibit IL-6–related RA disease activity

view transcript & references

References:

  • KEVZARA [prescribing information]. Bridgewater, NJ: Sanofi/Regeneron Pharmaceuticals, Inc.
  • Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424-1437.
  • Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49(1):15-24.
  • Astrakhantseva IV, Efimov GA, Drutskaya MS, Kruglov AA, Nedospasov SA. Modern anti-cytokine therapy of autoimmune diseases. Biochemistry (Mosc). 2014;79(12):1308-1321.